Key Points Moderna was known for its coronavirus vaccine a few years ago, but it’s greatly expanded its pipeline in recent years. Investors, recognizing the growth potential, piled into the stock this year, and it’s heading for a gain of more than 500%. 10 stocks we like better than Moderna › Moderna (NASDAQ: MRNA) delivered an enormous win for investors during the early days of the pandemic thanks to its leadership in the coronavirus vaccine market. But when demand for the vaccine, at the time the biotech's only commercialized product, declined, so did the company's earnings. And the stock followed, spending a few years in the doldrums. But in recent times, Moderna has made a turnaround.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.